Complement inhibitor dosing regimens
US-2026069653-A1 · Mar 12, 2026 · US
This page is not indexed by search engines while we improve data quality.
Deschatelets Pascal patents
Deschatelets Pascal is listed as an inventor on 70 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Deschatelets Pascal |
| Total patents | 70 |
| First publication | Jun 4, 2015 |
| Latest publication | Mar 12, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-2026062448-A1 · Mar 5, 2026 · US
Dosing regimens
US-12528836-B2 · Jan 20, 2026 · US
Dosing regimens and related compositions and methods
US-12458695-B2 · Nov 4, 2025 · US
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US-2025282823-A1 · Sep 11, 2025 · US
Dosing regimens and related compositions and methods
US-2025170210-A1 · May 29, 2025 · US
Dosing regimens and related compositions and methods
US-2025170209-A1 · May 29, 2025 · US
Dosing regimens and related compositions and methods
US-12290566-B2 · May 6, 2025 · US
Treatment of geographic atrophy
US-2025000936-A1 · Jan 2, 2025 · US
Dosing regimens
US-2024285725-A1 · Aug 29, 2024 · US
Recent patents
Latest publications not already listed above.
Dosing regimens and related compositions and methods
US-2024285783-A1 · Aug 29, 2024 · US
Dosing regimens and related compositions and methods
US-2024115655-A1 · Apr 11, 2024 · US
Genomic editing of complement
US-2024110182-A1 · Apr 4, 2024 · US
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-2024076317-A1 · Mar 7, 2024 · US
Dosing regimens
US-11903994-B2 · Feb 20, 2024 · US
Dosing regimens and related compositions and methods
US-11844841-B2 · Dec 19, 2023 · US
Methods of treating chronic disorders with complement inhibitors
US-11712460-B2 · Aug 1, 2023 · US
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-11661441-B2 · May 30, 2023 · US
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US-2023091471-A1 · Mar 23, 2023 · US
Treatment of paroxysmal nocturnal hemoglobinuria
US-2023076527-A1 · Mar 9, 2023 · US
Cell-penetrating compstatin analogs and uses thereof
US-2023075121-A1 · Mar 9, 2023 · US
Complement inhibitor dosing regimens
US-2022280598-A1 · Sep 8, 2022 · US
Cell-penetrating compstatin analogs and uses thereof
US-11407789-B2 · Aug 9, 2022 · US
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US-11292815-B2 · Apr 5, 2022 · US
Detection of high risk drusen
US-11291407-B2 · Apr 5, 2022 · US
Compositions and methods relating to c5l2
US-2022088131-A1 · Mar 24, 2022 · US
Methods of treating chronic disorders with complement inhibitors
US-2022040254-A1 · Feb 10, 2022 · US
Dosing regimens and related compositions and methods
US-2021401997-A1 · Dec 30, 2021 · US
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-2021292368-A1 · Sep 23, 2021 · US
Cell-penetrating compstatin analogs and uses thereof
US-2021198320-A1 · Jul 1, 2021 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Apellis Pharmaceuticals Inc | 70 |
| Francois Cedric | 4 |
| Deschatelets Pascal | 4 |
| King S College London | 3 |
| Zhang Zhouning | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.